70 datasets found
  1. Cancer Incidence - Surveillance, Epidemiology, and End Results (SEER)...

    • catalog.data.gov
    • healthdata.gov
    • +2more
    Updated Jul 26, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    National Cancer Institute (NCI), National Institutes of Health (NIH) (2023). Cancer Incidence - Surveillance, Epidemiology, and End Results (SEER) Registries Limited-Use [Dataset]. https://catalog.data.gov/dataset/cancer-incidence-surveillance-epidemiology-and-end-results-seer-registries-limited-use
    Explore at:
    Dataset updated
    Jul 26, 2023
    Dataset provided by
    National Cancer Institutehttp://www.cancer.gov/
    Description

    SEER Limited-Use cancer incidence data with associated population data. Geographic areas available are county and SEER registry. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute collects and distributes high quality, comprehensive cancer data from a number of population-based cancer registries. Data include patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage.

  2. Seer total equity 2020 to 2024

    • statista.com
    Updated May 8, 2025
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2025). Seer total equity 2020 to 2024 [Dataset]. https://www.statista.com/statistics/1524509/seer-total-equity/
    Explore at:
    Dataset updated
    May 8, 2025
    Dataset authored and provided by
    Statistahttp://statista.com/
    Area covered
    United States
    Description

    The total equity of Seer with headquarters in the United States amounted to 327.57 million U.S. dollars in 2024. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total decrease by approximately 104.04 million U.S. dollars. The trend from 2020 to 2024 shows, however, that this decrease did not happen continuously.

  3. Seer revenue 2020 to 2024

    • statista.com
    Updated May 8, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2025). Seer revenue 2020 to 2024 [Dataset]. https://www.statista.com/statistics/1523721/seer-revenue/
    Explore at:
    Dataset updated
    May 8, 2025
    Dataset authored and provided by
    Statistahttp://statista.com/
    Area covered
    United States
    Description

    The revenue of Seer with headquarters in the United States amounted to 14.2 million U.S. dollars in 2024. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total increase by approximately 13.5 million U.S. dollars. The trend from 2020 to 2024 shows, however, that this increase did not happen continuously.

  4. f

    Table_2_The Effectiveness of Different Treatment Modalities of Cutaneous...

    • frontiersin.figshare.com
    docx
    Updated Jun 3, 2023
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Siwei Bi; Shanshan Chen; Beiyi Wu; Ying Cen; Junjie Chen (2023). Table_2_The Effectiveness of Different Treatment Modalities of Cutaneous Angiosarcoma: Results From Meta-Analysis and Observational Data From SEER Database.docx [Dataset]. http://doi.org/10.3389/fonc.2021.627113.s002
    Explore at:
    docxAvailable download formats
    Dataset updated
    Jun 3, 2023
    Dataset provided by
    Frontiers
    Authors
    Siwei Bi; Shanshan Chen; Beiyi Wu; Ying Cen; Junjie Chen
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    IntroductionCutaneous angiosarcoma (cAS) is an aggressive vascular tumor that originates from vascular or lymphatic epithelial cells. To date, the cAS literature has been limited in a small number with single-center experiences or reports due to its rarity and the optimal treatment strategy is still in dispute. This study aimed to conduct a systematic review and compare the effect of available treatments retrieved from observational studies and Surveillance, Epidemiology, and End Results (SEER) program.MethodsThe authors performed a systematic review in the PubMed, Embase and MEDLINE database identifying the researches assessing the treatment for cAS patients. Clinical and treatment information of patients who had been diagnosed with a primary cAS were also obtained from the SEER program.ResultsThirty-two studies were eligible but only 5 of which with 276 patients were included in meta-analysis since the unclear or unavailable information. The risk ratio of 5-year death for surgery, surgery with radiotherapy and surgery with chemotherapy were 0.84, 0.96, and 0.69. Meanwhile, in SEER database, there are 291 metastatic and 437 localized patients with cAS. The localized patients receiving surgery showed a significantly worse overall survival result when compared with the surgery combined with RT: hazard ratio: 1.6, 95% confidential interval: 1.05, 2.42, P = 0.03.ConclusionIn conclusion, our study provided a detailed picture of the effectiveness of present treatments for localized and metastatic cAS patients. The CT could be inappropriate in localized patients. For metastatic patients, the surgery combined RT was recommended compared with surgery alone since its enhanced OS prognosis. Yet, more novel-designed clinical trials with specific targeted populations and rigorous conducting are needed for a solid conclusion on which would be a better treatment strategy.

  5. i

    Grant Giving Statistics for Seer 21 Inc.

    • instrumentl.com
    Updated Jul 7, 2021
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2021). Grant Giving Statistics for Seer 21 Inc. [Dataset]. https://www.instrumentl.com/990-report/seer-21-inc
    Explore at:
    Dataset updated
    Jul 7, 2021
    Description

    Financial overview and grant giving statistics of Seer 21 Inc.

  6. Seer net cash 2020 to 2024

    • statista.com
    Updated May 8, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2025). Seer net cash 2020 to 2024 [Dataset]. https://www.statista.com/statistics/1524205/seer-net-cash/
    Explore at:
    Dataset updated
    May 8, 2025
    Dataset authored and provided by
    Statistahttp://statista.com/
    Area covered
    United States
    Description

    The net cash of Seer with headquarters in the United States amounted to -46.11 million U.S. dollars in 2024. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total decrease by approximately 25.28 million U.S. dollars. The trend from 2020 to 2024 shows, however, that this decrease did not happen continuously.

  7. f

    The increasing toll of adolescent cancer incidence in the US

    • plos.figshare.com
    tiff
    Updated Jun 2, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Jessica Burkhamer; David Kriebel; Richard Clapp (2023). The increasing toll of adolescent cancer incidence in the US [Dataset]. http://doi.org/10.1371/journal.pone.0172986
    Explore at:
    tiffAvailable download formats
    Dataset updated
    Jun 2, 2023
    Dataset provided by
    PLOS ONE
    Authors
    Jessica Burkhamer; David Kriebel; Richard Clapp
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Cancer incidence is rising among adolescents (“teens”). The causes of the increase are unknown but studying incidence patterns and trends may produce insights into etiology. Using data from the US National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program we described trends of cancer incidence among teens (15–19 year olds). We reviewed and summarized incidence patterns for histologic cancer groups and the most frequently diagnosed sites of cancer among teens during 2008–2012 reported by the SEER Cancer Statistics Review. We calculated annual incidence rates for the years 1975–2012 and used linear regression analysis to evaluate trends and calculate rates of change. Incidence for all sites combined increased annually by 0.67% for males and 0.62% for females during the period 1975 through 2012 –resulting in more than a 25% increase over 38 years. The biggest annual incidence increases occurred in non-Hodgkin lymphoma (NHL) (2.16% females; 1.38% males), thyroid cancer (2.12% females; 1.59% males), acute myeloid leukemia (AML) (1.73% females) and testicular cancer (1.55% males). Incidence rates for most histologic groups and sites showed steady long term increases over the 38 years of data. Despite improvements in survival, rising incidence trends mean growing numbers of young adults are undergoing painful and costly cancer treatments. A concerted research program is vital to investigate causes of steadily rising teen cancer rates.

  8. M

    Seer Net Long-Term Debt 2020-2025 | SEER

    • macrotrends.net
    csv
    Updated Jun 30, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    MACROTRENDS (2025). Seer Net Long-Term Debt 2020-2025 | SEER [Dataset]. https://www.macrotrends.net/stocks/charts/SEER/seer/net-long-term-debt
    Explore at:
    csvAvailable download formats
    Dataset updated
    Jun 30, 2025
    Dataset authored and provided by
    MACROTRENDS
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Time period covered
    2010 - 2025
    Area covered
    United States
    Description

    Seer net long-term debt from 2020 to 2025. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately

  9. a

    5 year Colorectal Cancer Incidence MSSA

    • usc-geohealth-hub-uscssi.hub.arcgis.com
    Updated Nov 12, 2021
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Spatial Sciences Institute (2021). 5 year Colorectal Cancer Incidence MSSA [Dataset]. https://usc-geohealth-hub-uscssi.hub.arcgis.com/datasets/5-year-colorectal-cancer-incidence-mssa
    Explore at:
    Dataset updated
    Nov 12, 2021
    Dataset authored and provided by
    Spatial Sciences Institute
    Area covered
    Description

    Medical Service Study Areas (MSSAs)As defined by California's Office of Statewide Health Planning and Development (OSHPD) in 2013, "MSSAs are sub-city and sub-county geographical units used to organize and display population, demographic and physician data" (Source). Each census tract in CA is assigned to a given MSSA. The most recent MSSA dataset (2014) was used. Spatial data are available via OSHPD at the California Open Data Portal. This information may be useful in studying health equity.Age-Adjusted Incidence Rate (AAIR)Age-adjustment is a statistical method that allows comparisons of incidence rates to be made between populations with different age distributions. This is important since the incidence of most cancers increases with age. An age-adjusted cancer incidence (or death) rate is defined as the number of new cancers (or deaths) per 100,000 population that would occur in a certain period of time if that population had a 'standard' age distribution. In the California Health Maps, incidence rates are age-adjusted using the U.S. 2000 Standard Population.Cancer incidence ratesIncidence rates were calculated using case counts from the California Cancer Registry. Population data from 2010 Census and SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators. Yearly SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators for 5-year incidence rates (2013-2017)According to California Department of Public Health guidelines, cancer incidence rates cannot be reported if based on <15 cancer cases and/or a population <10,000 to ensure confidentiality and stable statistical rates.Spatial extent: CaliforniaSpatial Unit: MSSACreated: n/aUpdated: n/aSource: California Health MapsContact Email: gbacr@ucsf.eduSource Link: https://www.californiahealthmaps.org/?areatype=mssa&address=&sex=Both&site=AllSite&race=&year=05yr&overlays=none&choropleth=Obesity

  10. f

    AJU IB Investment Co Ltd reported holdings of SEER from Q1 2021 to Q1 2025

    • filingexplorer.com
    Updated Mar 31, 2021
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    FilingExplorer.com (2021). AJU IB Investment Co Ltd reported holdings of SEER from Q1 2021 to Q1 2025 [Dataset]. https://www.filingexplorer.com/form13f-holding/81578P106?cik=0001710065&period_of_report=2021-03-31
    Explore at:
    Dataset updated
    Mar 31, 2021
    Authors
    FilingExplorer.com
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Historical holdings data showing quarterly positions, market values, shares held, and portfolio percentages for SEER held by AJU IB Investment Co Ltd from Q1 2021 to Q1 2025

  11. i

    Grant Giving Statistics for Sight Seer Inc.

    • instrumentl.com
    Updated Jul 6, 2021
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2021). Grant Giving Statistics for Sight Seer Inc. [Dataset]. https://www.instrumentl.com/990-report/sight-seer-inc
    Explore at:
    Dataset updated
    Jul 6, 2021
    Variables measured
    Total Assets
    Description

    Financial overview and grant giving statistics of Sight Seer Inc.

  12. Sri Lanka Retail Price: Seer Fish

    • ceicdata.com
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    CEICdata.com, Sri Lanka Retail Price: Seer Fish [Dataset]. https://www.ceicdata.com/en/sri-lanka/retail-price-by-commodity/retail-price-seer-fish
    Explore at:
    Dataset provided by
    CEIC Data
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Time period covered
    Jan 1, 2017 - Dec 1, 2017
    Area covered
    Sri Lanka
    Variables measured
    Domestic Trade Price
    Description

    Sri Lanka Retail Price: Seer Fish data was reported at 1,341.790 LKR/kg in Aug 2018. This records an increase from the previous number of 1,323.230 LKR/kg for Jul 2018. Sri Lanka Retail Price: Seer Fish data is updated monthly, averaging 312.700 LKR/kg from Jan 1984 (Median) to Aug 2018, with 416 observations. The data reached an all-time high of 1,341.790 LKR/kg in Aug 2018 and a record low of 43.360 LKR/kg in Jan 1984. Sri Lanka Retail Price: Seer Fish data remains active status in CEIC and is reported by Central Bank of Sri Lanka. The data is categorized under Global Database’s Sri Lanka – Table LK.P004: Retail Price: By Commodity.

  13. Seer liabilities 2020 to 2024

    • statista.com
    Updated May 8, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2025). Seer liabilities 2020 to 2024 [Dataset]. https://www.statista.com/statistics/1524055/seer-liabilities/
    Explore at:
    Dataset updated
    May 8, 2025
    Dataset authored and provided by
    Statistahttp://statista.com/
    Area covered
    United States
    Description

    The liabilities of Seer with headquarters in the United States amounted to 39.03 million U.S. dollars in 2024. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total increase by approximately 28.32 million U.S. dollars. The trend from 2020 to 2024 shows, however, that this increase did not happen continuously.

  14. A

    ‘COVID-19 Cases and Deaths by Race/Ethnicity’ analyzed by Analyst-2

    • analyst-2.ai
    Updated Sep 29, 2021
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Analyst-2 (analyst-2.ai) / Inspirient GmbH (inspirient.com) (2021). ‘COVID-19 Cases and Deaths by Race/Ethnicity’ analyzed by Analyst-2 [Dataset]. https://analyst-2.ai/analysis/data-gov-covid-19-cases-and-deaths-by-race-ethnicity-3781/latest
    Explore at:
    Dataset updated
    Sep 29, 2021
    Dataset authored and provided by
    Analyst-2 (analyst-2.ai) / Inspirient GmbH (inspirient.com)
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Analysis of ‘COVID-19 Cases and Deaths by Race/Ethnicity’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/3fdc6593-c708-4a6a-8073-5ca862caa279 on 27 January 2022.

    --- Dataset description provided by original source is as follows ---

    COVID-19 cases and associated deaths that have been reported among Connecticut residents, broken down by race and ethnicity. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Deaths reported to the either the Office of the Chief Medical Examiner (OCME) or Department of Public Health (DPH) are included in the COVID-19 update.

    The following data show the number of COVID-19 cases and associated deaths per 100,000 population by race and ethnicity. Crude rates represent the total cases or deaths per 100,000 people. Age-adjusted rates consider the age of the person at diagnosis or death when estimating the rate and use a standardized population to provide a fair comparison between population groups with different age distributions. Age-adjustment is important in Connecticut as the median age of among the non-Hispanic white population is 47 years, whereas it is 34 years among non-Hispanic blacks, and 29 years among Hispanics. Because most non-Hispanic white residents who died were over 75 years of age, the age-adjusted rates are lower than the unadjusted rates. In contrast, Hispanic residents who died tend to be younger than 75 years of age which results in higher age-adjusted rates.

    The population data used to calculate rates is based on the CT DPH population statistics for 2019, which is available online here: https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Population-Statistics. Prior to 5/10/2021, the population estimates from 2018 were used.

    Rates are standardized to the 2000 US Millions Standard population (data available here: https://seer.cancer.gov/stdpopulations/). Standardization was done using 19 age groups (0, 1-4, 5-9, 10-14, ..., 80-84, 85 years and older). More information about direct standardization for age adjustment is available here: https://www.cdc.gov/nchs/data/statnt/statnt06rv.pdf

    Categories are mutually exclusive. The category “multiracial” includes people who answered ‘yes’ to more than one race category. Counts may not add up to total case counts as data on race and ethnicity may be missing. Age adjusted rates calculated only for groups with more than 20 deaths. Abbreviation: NH=Non-Hispanic.

    Data on Connecticut deaths were obtained from the Connecticut Deaths Registry maintained by the DPH Office of Vital Records. Cause of death was determined by a death certifier (e.g., physician, APRN, medical examiner) using their best clinical judgment. Additionally, all COVID-19 deaths, including suspected or related, are required to be reported to OCME. On April 4, 2020, CT DPH and OCME released a joint memo to providers and facilities within Connecticut providing guidelines for certifying deaths due to COVID-19 that were consistent with the CDC’s guidelines and a reminder of the required reporting to OCME.25,26 As of July 1, 2021, OCME had reviewed every case reported and performed additional investigation on about one-third of reported deaths to better ascertain if COVID-19 did or did not cause or contribute to the death. Some of these investigations resulted in the OCME performing postmortem swabs for PCR testing on individuals whose deaths were suspected to be due to COVID-19, but antemortem diagnosis was unable to be made.31 The OCME issued or re-issued about 10% of COVID-19 death certificates and, when appropriate, removed COVID-19 from the death certificate. For standardization and tabulation of mortality statistics, written cause of death statements made by the certifiers on death certificates are sent to the National Center for Health Statistics (NCHS) at the CDC which assigns cause of death codes according to the International Causes of Disease 10th Revision (ICD-10) classification system.25,26 COVID-19 deaths in this report are defined as those for which the death certificate has an ICD-10 code of U07.1 as either a primary (underlying) or a contributing cause of death. More infor

    --- Original source retains full ownership of the source dataset ---

  15. Seer operating profit 2020 to 2024

    • statista.com
    Updated May 8, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2025). Seer operating profit 2020 to 2024 [Dataset]. https://www.statista.com/statistics/1523927/seer-operating-profit/
    Explore at:
    Dataset updated
    May 8, 2025
    Dataset authored and provided by
    Statistahttp://statista.com/
    Area covered
    United States
    Description

    The operating profit of Seer with headquarters in the United States amounted to -100.1 million U.S. dollars in 2024. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total decrease by approximately 66.45 million U.S. dollars. The trend from 2020 to 2024 shows, however, that this decrease did not happen continuously.

  16. a

    5 year Female Colorectal Cancer Incidence MSSA

    • usc-geohealth-hub-uscssi.hub.arcgis.com
    Updated Nov 12, 2021
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Spatial Sciences Institute (2021). 5 year Female Colorectal Cancer Incidence MSSA [Dataset]. https://usc-geohealth-hub-uscssi.hub.arcgis.com/datasets/5-year-female-colorectal-cancer-incidence-mssa
    Explore at:
    Dataset updated
    Nov 12, 2021
    Dataset authored and provided by
    Spatial Sciences Institute
    Area covered
    Description

    Medical Service Study Areas (MSSAs)As defined by California's Office of Statewide Health Planning and Development (OSHPD) in 2013, "MSSAs are sub-city and sub-county geographical units used to organize and display population, demographic and physician data" (Source). Each census tract in CA is assigned to a given MSSA. The most recent MSSA dataset (2014) was used. Spatial data are available via OSHPD at the California Open Data Portal. This information may be useful in studying health equity.Age-Adjusted Incidence Rate (AAIR)Age-adjustment is a statistical method that allows comparisons of incidence rates to be made between populations with different age distributions. This is important since the incidence of most cancers increases with age. An age-adjusted cancer incidence (or death) rate is defined as the number of new cancers (or deaths) per 100,000 population that would occur in a certain period of time if that population had a 'standard' age distribution. In the California Health Maps, incidence rates are age-adjusted using the U.S. 2000 Standard Population.Cancer incidence ratesIncidence rates were calculated using case counts from the California Cancer Registry. Population data from 2010 Census and SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators. Yearly SEER 2015 census tract estimates by race/origin (controlling to Vintage 2015) were used to estimate population denominators for 5-year incidence rates (2013-2017)According to California Department of Public Health guidelines, cancer incidence rates cannot be reported if based on <15 cancer cases and/or a population <10,000 to ensure confidentiality and stable statistical rates.Spatial extent: CaliforniaSpatial Unit: MSSACreated: n/aUpdated: n/aSource: California Health MapsContact Email: gbacr@ucsf.eduSource Link: https://www.californiahealthmaps.org/?areatype=mssa&address=&sex=Both&site=AllSite&race=&year=05yr&overlays=none&choropleth=Obesity

  17. f

    Table_1_The Effectiveness of Different Treatment Modalities of Cutaneous...

    • figshare.com
    docx
    Updated May 31, 2023
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Siwei Bi; Shanshan Chen; Beiyi Wu; Ying Cen; Junjie Chen (2023). Table_1_The Effectiveness of Different Treatment Modalities of Cutaneous Angiosarcoma: Results From Meta-Analysis and Observational Data From SEER Database.docx [Dataset]. http://doi.org/10.3389/fonc.2021.627113.s001
    Explore at:
    docxAvailable download formats
    Dataset updated
    May 31, 2023
    Dataset provided by
    Frontiers
    Authors
    Siwei Bi; Shanshan Chen; Beiyi Wu; Ying Cen; Junjie Chen
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    IntroductionCutaneous angiosarcoma (cAS) is an aggressive vascular tumor that originates from vascular or lymphatic epithelial cells. To date, the cAS literature has been limited in a small number with single-center experiences or reports due to its rarity and the optimal treatment strategy is still in dispute. This study aimed to conduct a systematic review and compare the effect of available treatments retrieved from observational studies and Surveillance, Epidemiology, and End Results (SEER) program.MethodsThe authors performed a systematic review in the PubMed, Embase and MEDLINE database identifying the researches assessing the treatment for cAS patients. Clinical and treatment information of patients who had been diagnosed with a primary cAS were also obtained from the SEER program.ResultsThirty-two studies were eligible but only 5 of which with 276 patients were included in meta-analysis since the unclear or unavailable information. The risk ratio of 5-year death for surgery, surgery with radiotherapy and surgery with chemotherapy were 0.84, 0.96, and 0.69. Meanwhile, in SEER database, there are 291 metastatic and 437 localized patients with cAS. The localized patients receiving surgery showed a significantly worse overall survival result when compared with the surgery combined with RT: hazard ratio: 1.6, 95% confidential interval: 1.05, 2.42, P = 0.03.ConclusionIn conclusion, our study provided a detailed picture of the effectiveness of present treatments for localized and metastatic cAS patients. The CT could be inappropriate in localized patients. For metastatic patients, the surgery combined RT was recommended compared with surgery alone since its enhanced OS prognosis. Yet, more novel-designed clinical trials with specific targeted populations and rigorous conducting are needed for a solid conclusion on which would be a better treatment strategy.

  18. I

    India Imports: USD: HS: 03045990: Other Excluding Hilsa, Shark, Seer, Tuna

    • ceicdata.com
    Updated Jan 25, 2025
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    CEICdata.com (2025). India Imports: USD: HS: 03045990: Other Excluding Hilsa, Shark, Seer, Tuna [Dataset]. https://www.ceicdata.com/en/india/foreign-trade-harmonized-system-8-digits-by-commodity-hs03-fish-and-crustaceans-imports-usd/imports-usd-hs-03045990-other-excluding-hilsa-shark-seer-tuna
    Explore at:
    Dataset updated
    Jan 25, 2025
    Dataset provided by
    CEICdata.com
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Time period covered
    Mar 1, 2014 - Mar 1, 2018
    Area covered
    India
    Variables measured
    Merchandise Trade
    Description

    India Imports: USD: HS: 03045990: Other Excluding Hilsa, Shark, Seer, Tuna data was reported at 0.090 USD mn in 2018. This records a decrease from the previous number of 0.290 USD mn for 2016. India Imports: USD: HS: 03045990: Other Excluding Hilsa, Shark, Seer, Tuna data is updated yearly, averaging 0.275 USD mn from Mar 2014 (Median) to 2018, with 4 observations. The data reached an all-time high of 0.540 USD mn in 2015 and a record low of 0.090 USD mn in 2018. India Imports: USD: HS: 03045990: Other Excluding Hilsa, Shark, Seer, Tuna data remains active status in CEIC and is reported by Ministry of Commerce and Industry. The data is categorized under India Premium Database’s Foreign Trade – Table IN.JAF005: Foreign Trade: Harmonized System 8 Digits: By Commodity: HS03: Fish and Crustaceans: Imports: USD.

  19. m

    Data from: Disease-Specific Survival in Patients with Invasive Amelanotic...

    • data.mendeley.com
    Updated Jun 9, 2025
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Nguyễn Tráng (2025). Disease-Specific Survival in Patients with Invasive Amelanotic Melanoma: Insights from SEER Database Analysis (2000-2021) [Dataset]. http://doi.org/10.17632/jcd827xvgg.1
    Explore at:
    Dataset updated
    Jun 9, 2025
    Authors
    Nguyễn Tráng
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Supplementary materials of the brief report title "Disease-Specific Survival in Patients with Invasive Amelanotic Melanoma: Insights from SEER Database Analysis (2000-2021)"

  20. w

    Global Ev Co2 Heat Pump Systems Market Research Report: By Compressor Type...

    • wiseguyreports.com
    Updated Sep 24, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    wWiseguy Research Consultants Pvt Ltd (2024). Global Ev Co2 Heat Pump Systems Market Research Report: By Compressor Type (Scroll Compressor, Reciprocating Compressor, Rotary Compressor, Twin-Screw Compressor), By Heat Source (Air, Ground, Water), By Application (Residential, Commercial, Industrial), By Capacity (10 kW, 10-20 kW, 20-30 kW, >30 kW), By Efficiency Level (SEER 13-15, SEER 16-18, SEER 19-21, SEER 22+) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032. [Dataset]. https://www.wiseguyreports.com/reports/ev-co2-heat-pump-systems-market
    Explore at:
    Dataset updated
    Sep 24, 2024
    Dataset authored and provided by
    wWiseguy Research Consultants Pvt Ltd
    License

    https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy

    Time period covered
    Jan 9, 2024
    Area covered
    Global
    Description
    BASE YEAR2024
    HISTORICAL DATA2019 - 2024
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    MARKET SIZE 20239.69(USD Billion)
    MARKET SIZE 202411.5(USD Billion)
    MARKET SIZE 203245.0(USD Billion)
    SEGMENTS COVEREDCompressor Type ,Heat Source ,Application ,Capacity ,Efficiency Level ,Regional
    COUNTRIES COVEREDNorth America, Europe, APAC, South America, MEA
    KEY MARKET DYNAMICSRising consumer demand Technological advancements Increasing environmental concerns Government incentives Expanding automotive industry
    MARKET FORECAST UNITSUSD Billion
    KEY COMPANIES PROFILEDFujitsu General ,Lennox International ,Emerson Electric ,Hitachi Global Life Solutions ,Samsung Electronics ,LG Electronics ,Johnson Controls ,Trane Technologies ,Panasonic ,Gree Electric Appliances ,Daikin Industries ,Danfoss ,Midea Group ,Mitsubishi Electric ,Carrier Global
    MARKET FORECAST PERIOD2025 - 2032
    KEY MARKET OPPORTUNITIESGrowth in EV sales Government incentives Increasing demand for energyefficient solutions Technological advancements Expanding applications in commercial and industrial sectors
    COMPOUND ANNUAL GROWTH RATE (CAGR) 18.6% (2025 - 2032)
Share
FacebookFacebook
TwitterTwitter
Email
Click to copy link
Link copied
Close
Cite
National Cancer Institute (NCI), National Institutes of Health (NIH) (2023). Cancer Incidence - Surveillance, Epidemiology, and End Results (SEER) Registries Limited-Use [Dataset]. https://catalog.data.gov/dataset/cancer-incidence-surveillance-epidemiology-and-end-results-seer-registries-limited-use
Organization logo

Cancer Incidence - Surveillance, Epidemiology, and End Results (SEER) Registries Limited-Use

Explore at:
4 scholarly articles cite this dataset (View in Google Scholar)
Dataset updated
Jul 26, 2023
Dataset provided by
National Cancer Institutehttp://www.cancer.gov/
Description

SEER Limited-Use cancer incidence data with associated population data. Geographic areas available are county and SEER registry. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute collects and distributes high quality, comprehensive cancer data from a number of population-based cancer registries. Data include patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage.

Search
Clear search
Close search
Google apps
Main menu